{"prompt": "['S.', 'On treatment days, blood collection should occur within 2 hours prior to emicizumab administration unless otherwise specified. Samples for this assessment', 'be taken prior to emicizumab injection. Unless otherwise specified, On days where samples are to be collected, emicizumal injection will be performed in', \"the clinical unit.additional analysis will be performed at a local laboratory, as per the investigator's discretion. Any additional laboratory results which are required as\", \"part of the patient's safety assessment should be recorded in the unscheduled visit eCRFs. Central labs are part of the non-eCRF data which will be sent to the Sponsor\", 'directly by the central lab vendor.', 't.', 'Plasma samples are required for PK assessments. On days where samples are to be collected, the emicizumab injection will be performed in the clinical unit. One', 'single pre-dose sample is required on the applicable visits. All biomarker assessments will be conducted at aSamples will be analysed by the central laboratory.-', \"Additional analysis will be performed at a local laboratory, as per the investigator's discretion.\", 'u.', 'Plasma samples for safety biomarkers must be citrate plasma. Tests may include, but are not limited to, D-dimer. Samples will be analysed by the central laboratory.', 'See Appendix 2. ma samples for D dimer testing will be taken at the visits indicated.', 'V. Plasma samples for safety coagulation system biomarker assessments must be citrate plasma. Tests include (FVIII:Ag, FIX:Ag and FX:Ag.) will be taken', 'at the visits indicated. Samples will be analysed by the central laboratory. See Appendix 2.', 'W.', 'Plasma samples for PD biomarker assessments must be citrate plasma. Tests will include, but are not limited to, FVIII activity and modified aPTT (one stage).', 'will beTime windows for sample collection are specified in Appendix 2', 'Schedule of Biomarker Samples', 'X.', 'assessed at Week 1 (Day 1, Cycle 1); Week 5 (+ 2 days); 3 and 6 months (+ 7 days); 12 months (+ 14 days); and 18 months and study completion (+', '30 days). samples must be citrate plasma Additional plasma samples will be collected for future exploratory research, which may include tests such', 'as clot waveform analysis (CWA) and others (see Appendix 2', 'Schedule of Biomarker Samples', 'y.', '). Samples will be analysed by the central laboratory.', 'z.', 'joint biomarkers will be assessed at Week 1 (Day 1, Cycle 1); 6 months (+ days); and 18 months and study completion (+', 'and plasma EDTA samples for bone and joint biomarkers must be collected after fasting (no food or drink other than water for at least 8 hours prior to the', 'blood draw). Ideally these samples should be collected in the morning (before noon), in order to control for diurnal variation. Please', 'consult', 'the', 'Central', 'Laboratory Services Manual for details. The selection of exploratory bone and joint biomarkers to be tested will build on findings', 'from', 'biomarker', 'analyses', 'in other emicizumab trials and may include CTX-1, OPG, P1NP, and soluble RANK-L (see Appendix 2', 'Schedule of Biomarker Samples', 'aa. ). Samples will be analysed by the central laboratory.', 'bb. Additional laboratory assessments: In the event of a breakthrough bleed that is treated with bypassing agents, it is recommended that the following laboratory tests', 'will be performed within 24-48 hours of initial bypassing agent use (these tests will be conducted so that the investigator can monitor the patient for potential', 'thromboembolic events and microangiopathic hemolytic anemia or TMA). These tests include platelet count, serum creatinine, LDH and schistocytes. A plasma sample', 'should also be provided for central laboratory monitoring of prothrombin fragment F1+2, fibrinogen and D-dimer. Samples for these tests should ideally be', 'analysed at the central laboratory. Exceptionally in urgent situations where results are required quickly, local laboratory testing can be used, with results recorded in', 'the eCRF. For patients who require multiple doses of bypassing agents, laboratory monitoring should be performed every 24-48 hours until', '24-48', 'hours', 'after', 'the', 'last', 'dose of bypassing agents is administered to treat a specific bleed. If applicable, laboratory results should be recorded in the unscheduled visit eCRFs.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '53 / Protocol MO39129, Version 3']['Appendix 2', 'Schedule of Biomarker Samples', 'Time', 'Sample', 'Visit [a]', 'window', 'Biomarker assays [b,e]', 'Safety biomarkers [c]', 'Week 1', 'Day 1', 'May include, but are not limited to, D-dimer', 'Week 5', '+ 2 days', '3 months', '+ 7 days', '6 months', '+ 7 days', '12 months', '+ 14 days', '18 months', '30 days', 'Study completion', '+ 30 days', 'Safety Follow-up', 'Visit (if applicable)', 'Safety coagulation', 'Week 1', 'Day 1', 'FVIII:Ag, FIX:Ag and FX:Ag', 'system biomarkers [c]', 'Week 5', '+ 2 days', 'PD biomarkers [cd,e]', 'Week 1', 'Day 1', 'Will include, but are not limited to:', 'FVIII inhibitor titer, Modified aPTT (one-', 'Week 5', '2 days', 'stage), FVIII activity', '3 months', '+ 7 days', '6 months', '7 days', '12 months', '+ 14 days', '18 months', '+ 30 days', 'Study completion', '+ 30 days', 'Bone and joint', 'Week 1', 'Day 1', 'Exploratory biomarkers of bone turnover', 'biomarkers (fasting)', 'and joint health [e]', '6 months', '[df,g]', '+ 7 days', '18 months', '+ 30 days', 'Study completion', '+ 30 days', 'aPTT=activated partial thromboplastin time; CTX-1=C-terminal telopeptide of collagen 1; CWA=clot', 'waveform', 'analysis;', 'IDTA=ethylenediaminetetraacetic', 'acid;', 'DPG=osteoprotegerin;', 'P1NP=procollagen type 1 amino-terminal propeptide; PD=pharmacodynamic; RANK-L=receptor', 'activator of nuclear factor kappa-B ligand', 'Except for Day 1 of Cycle 1, all other study visits and assessments should be conducted within', 'the', 'following timeframes Week 5, 2 days; 3 and 6 months, 7 days; 12 months, I 14 days;', '18 months and study completion 30 days.', 'a.', 'All samples are to be collected within 2 hours prior to emicizumab injection (if applicable) unless', 'otherwise specified.', 'b. Assays that will be tested are listed. Blood volumes and processing procedures will be specified', 'in the Central Laboratory Services Manual. Biomarker assessments will be conducted at the central', \"laboratory. Additional analysis will be performed at a local laboratory, as per the investigator's discretion.\", 'G.', 'SBiomarker assessments will be conducted at a central laboratory. Additional analysis will be', \"performed at a local laboratory, as per the investigator' discretion.\", 'Emicizumab - F. Hoffmann-La Roche Ltd', '54 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}